BLAINJECTIONINJECTABLE
Approved
Sep 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
AMJEVITA (adalimumab-atto) by Amgen is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2016.
Drug data last refreshed 20h ago
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Amgen
THOUSAND OAKS, CA
Worked on AMJEVITA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.